

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

23. - 34 (Canceled)

35. (Withdrawn-Amended) The ~~drug~~ composition according to claim 47 [[31]], wherein the active apoptosis-inducing or proliferation-inhibiting compound is a death receptor ligand, derivative or fragment thereof.

36. (Withdrawn-Amended) The ~~drug~~ composition according to claim 35, wherein the death receptor ligand is selected from the group consisting of tumor necrosis factor α (TNF- α), tumor necrosis factor β (TNF- β , lymphotoxin- α), LT- β (lymphotoxin- β), TRAIL (Apo2L), CD95 (Fas, APO-1) ligand, TRAMP (DR3, Apo-3) ligand, DR4 ligand, DR6 ligand as well as fragments and derivatives of any of said ligands.

37. (Withdrawn-Amended) The ~~drug~~ composition according to claim 36, wherein the death receptor ligand is TRAIL.

38. (Withdrawn-Amended) The ~~drug~~ composition according to claim 47 [[31]], wherein the active apoptosis-inducing or proliferation-inhibiting compound is an antibody against a death receptor, a derivative or fragment thereof.

39. (Withdrawn-Amended) The ~~drug~~ composition according to claim 38, wherein the antibody against the death receptor ligand is selected from the group consisting of anti-CD95 antibody, anti-TRAIL-R1 (DR4) antibody, anti-TRAIL-R2 (DR5) antibody, anti-DR6 antibody, anti TNF-R1 antibody and anti-TRAMP (DR3) antibody as well as fragments and derivatives of any of said antibodies.

40. (Withdrawn-Amended) The ~~drug~~ composition according to claim 39, wherein the antibody against the death receptor is the anti-CD95 antibody.

41. (Withdrawn-Amended) A method of treating cancer in a human or an animal, which method comprises administering ~~[[of]]~~ a ~~[[Smac/carrier]]~~ Smac carrier entity according to claim 45 ~~[[23]]~~, optionally in combination with at least one active apoptosis-inducing compound.

42. (Withdrawn) The method according to claim 41, wherein the cancer to be treated is selected from a group consisting of neuroblastoma, rectum carcinoma, colon carcinoma, familial adenomatous polyposis carcinoma, hereditary non-polyposis colorectal cancer, esophageal carcinoma, labial carcinoma, larynx carcinoma, hypopharynx carcinoma, tongue carcinoma, salivary gland carcinoma, gastric carcinoma, adenocarcinoma, medullary thyroid carcinoma, papillary thyroid carcinoma, renal carcinoma, kidney parenchyma carcinoma, ovarian carcinoma, cervix carcinoma, uterine corpus carcinoma, endometrium carcinoma, chorion carcinoma, pancreatic carcinoma, prostate carcinoma, testis carcinoma, breast carcinoma, urinary carcinoma, melanoma, brain tumors preferably glioblastoma, astrocytoma, meningioma, medulloblastoma and peripheral neuroectodermal tumors, Hodgkin lymphoma, non-Hodgkin lymphoma, Burkitt lymphoma, acute lymphatic leukemia (ALL), chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, hepatocellular carcinoma, gall bladder carcinoma, bronchial carcinoma, small cell lung carcinoma, non-small cell lung carcinoma, multiple myeloma, basaloma, teratoma, retinoblastoma, choroid melanoma, seminoma, rhabdomyosarcoma, craniopharyngeoma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmacytoma.

43. (Withdrawn) The method according to claim 42, wherein the cancer to be treated is selected from the group consisting of neuroblastoma, glioblastoma, breast carcinoma, melanoma, prostate cancer and pancreatic carcinoma.

44. Canceled

45. (New) A Smac carrier entity comprising:

(i) a Smac protein comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:1; amino acids 56 to 59 of SEQ ID NO:1; amino acids 56 to 62 of SEQ ID NO:1; and amino acids 56 to 70 of SEQ ID NO:1; and

(ii) a carrier comprising the human deficiency virus-1 TAT protein (trans-activating protein) comprising the amino acid sequence of SEQ ID NO:3, wherein the Smac protein and the carrier are linked together by a chemical bond enabling the penetration of the Smac carrier entity through the cell membrane into the cell.

46. (New) A Smac carrier entity comprising:

(i) a Smac protein comprising the amino acid sequence selected from the group consisting of: SEQ ID NO:1; amino acids 56 to 59 of SEQ ID NO:1; amino acids 56 to 62 of SEQ ID NO:1; and amino acids 56 to 70 of SEQ ID NO:1; and

(ii) a carrier comprising the human deficiency virus-1 TAT protein (trans-activating protein) comprising the amino acid sequence of amino acids 47 to 57 SEQ ID NO:3 or 37 to 72 of SEQ ID NO:3, wherein the Smac protein and the carrier are linked together by a chemical bond enabling the penetration of the Smac carrier entity through the cell membrane into the cell.

47. (New) A composition comprising the Smac carrier entity of claim 45, optionally in combination with at least one active apoptosis-inducing or proliferation-inhibiting compound and a pharmaceutically acceptable carrier.

48. (New) The composition of claim 47, wherein the active apoptosis-inducing or proliferation-inhibiting compound is a cytostatic compound.

49. (New) The composition of claim 48, wherein the cytostatic compound is doxorubicin.

50. (New) A composition comprising the Smac carrier entity of claim 46, optionally in combination with at least one active apoptosis-inducing or proliferation-inhibiting compound and a pharmaceutically acceptable carrier.

51. (New) The composition of claim 50, wherein the active apoptosis-inducing or proliferation-inhibiting compound is a cytostatic compound.

52. (New) The composition of claim 51, wherein the cytostatic compound is doxorubicin.